Aesku.Group GmbH products

AESKULISA for qualitative and quantitative demonstration of IgA, IgG, or IgM antibodies directed against a range of different pathogens supporting a reliable diagnosis of infectious diseases.

The AESKU.RAPID SARS-CoV-2 Rapid Test is based on immunochromatographic polymer technology combined with the sandwich principle for the qualitative detection of the nucleocapsid protein antigen in human nasal swab specimens. The specimen is placed in the test device`s specimen well with colored polymer-labeled monoclonal SARS-CoV-2 antibody 1 and mixed along the nitrocellulose membrane chromatographed. If SARS-CoV-2 antigens are present in the sample, they bind to the SARS-CoV-2 antibody 1.The mixture then binds to the immobilized SARS-CoV-2 antibody 2 on the nitrocellulose membrane. The resulting complex of antibody 1, antigen, and antibody 2 forms the colored test line. The test device`s control line is coated with secondary antibodies, which, under normal test procedure, a colored strip is drawn.